Advanced Filters
noise

Male Pattern Baldness Clinical Trials

A listing of Male Pattern Baldness medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 272 clinical trials
G Geert D'Haens, Prof

inDuctIon tREatment With subCuTaneous Infliximab for Crohn's Disease

Study Design: A Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous (SC) Infliximab (IFX) with and without Immunomodulators during Induction treatment in Moderate to Severe Crohn's Disease. Primary endpoint: The proportion of patients in corticosteroid-free clinical remission (as defined by a Crohn's disease activity index …

18 - 80 years of age All Phase 3
N Nitsan Maharshak, PhD

The Assessment of Infrared Treatment for Crohn's Disease

The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients. The main questions it aims to answer are: Is infrared therapy safe for treating Crohn's disease patients? Is infrared therapy effective for treating Crohn's disease? Participants will be …

18 - 80 years of age All Phase N/A
S Study Coordinator

Treatment of Moderate to Severe Refractory Crohn's Disease

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

18 - 65 years of age All Phase 1/2
D David T Gonzalez, RN

HB-adMSCs for the Treatment of Crohn's Disease

Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post first treatment. Treatment Duration: 16 weeks General Objectives: To assess the efficacy and safety of …

18 - 65 years of age All Phase 2
C Céline Roman, MD, PhD

Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.

This research is a multicenter French randomized and single blinded phase III clinical trial evaluating two treatment strategies among Crohn's disease (CD) patients. The main objective is to assess if the addition of Crohn's Disease Exclusion Diet (CDED) to ongoing standard medication is superior to reduce the rate of relapses …

6 - 17 years of age All Phase 3
S Salih Tokmak

Exclusive Enteral Nutrition in Patients With Ileocaecal Crohn's Disease

Inflammatory bowel diseases are chronic and progressive entities, triggered by exposure to environmental factors in individuals with a genetic background. One of the most common environmental factors is the type of diet which is a key influencer on pathogenesis. Nutrients alter the intestinal microbiota, thus changing the intestinal permeability. The …

18 - 75 years of age All Phase 3
C Chunhui Bao, MD, PhD

Effect of Acupuncture on Mild to Moderate Active Crohn's Disease

To observe the clinical effect of acupuncture on Crohn's disease (CD) and its influence on brain function activity and the TRY-KYN metabolism level, and to screen the brain image markers of acupuncture on CD

16 - 70 years of age All Phase N/A
R Richelle L Bearup, MPH

Low Dose IL-2 for the Treatment of Crohn's Disease

The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.

18 - 80 years of age All Phase 1/2
J Jessica K Salwen-Deremer, PhD

RISE: A Remote Study of Insomnia Treatment in Crohn's Disease

The purpose of this study is to assess whether the investigators can treat insomnia in people with Crohn's disease, and if insomnia treatment can make other things better, like pain or inflammation.

18 years of age All Phase N/A
E Eun Ja Youn, RN

TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease

This study will compare the efficacy and safety of TDM (therapeutic drug monitoring)-based infliximab (CT-P13, RemsimaTM) intravenous therapy compared with the standard infliximab (RemsimaTM) intravenous therapy for patients with active perianal fistulzing Crohn's disease.

19 - 80 years of age All Phase 4

Simplify language using AI